Analyst Ami Fadia of Needham reiterated a Buy rating on Day One Biopharmaceuticals (DAWN – Research Report), reducing the price target to $32.00.
Ami Fadia has given his Buy rating due to a combination of factors that highlight the potential for Day One Biopharmaceuticals’ continued growth. The company’s recent earnings report showed stable revenue from Ojemda, driven by an increase in new patient additions and a high retention rate of patients on therapy. Additionally, the improvement in gross-to-net adjustments, following the CMS approval for a pediatric designation, further supports the company’s financial outlook.
Ami Fadia also notes the strategic investment in research and development, particularly the in-licensing of DAY301, which indicates a commitment to expanding the company’s pipeline. The focus on commercial execution of Ojemda in the second-line treatment of pediatric low-grade glioma (pLGG) and the anticipated completion of enrollment for pipeline agents like DAY-301 and tovo in first-line pLGG by the first half of 2026, are seen as positive indicators for future growth. These elements collectively contribute to the Buy rating, reflecting confidence in the company’s strategic direction and market potential.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $34.00 price target.